GlaxoSmithKline strikes government deal to provide Relenza for state stockpiles

By Jennifer Chiou

New York, July 20 - GlaxoSmithKline said it reached a two-year agreement with the U.S. government to supply its anti-viral Relenza in preparation for a potential influenza pandemic.

The London-based pharmaceutical company said that the Department of Health and Human Services is guaranteeing the initial purchase of $16.8 million of Relenza.

GlaxoSmithKline noted that the purchase will help states to begin adding Relenza to their pandemic stockpiles at a federally subsidized price.

The company said that the government has purchased, to date, about 4 million treatment courses of Relenza, which is approved for both the prophylaxis and treatment of influenza A and B in children and adults.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.